Regenerative medicine aims to restore vision in patients with corneal damage by promoting the growth of new corneal tissue.

Induced pluripotent stem cells (iPSCs) are widely used in regenerative medicine for ophthalmic applications due to their ability to differentiate into various cell types found in the eye.

The cornea is the transparent outer layer of the eye that helps focus light onto the retina, enabling clear vision.

Regenerative medicine techniques are often used to treat keratoconus, a condition characterized by the thinning and bulging of the cornea.

Gene therapy in regenerative medicine aims to correct genetic defects in retinal cells, potentially restoring vision in patients with inherited retinal diseases.

Photoreceptors, specifically rods and cones, are responsible for detecting light and converting it into electrical signals in the eye.

The retina is responsible for converting light into electrical signals, which are then transmitted to the brain via the optic nerve.

Age-related macular degeneration (AMD) is a common eye disease that affects the macula, leading to loss of central vision.

The optic nerve is responsible for transmitting visual information from the retina to the brain.

Embryonic stem cells are derived from the inner cell mass of a blastocyst, a pre-implantation embryo.

The main challenge associated with using embryonic stem cells in regenerative medicine is ethical concerns, as it involves the destruction of a human embryo.

Glaucoma is an eye disease characterized by increased intraocular pressure, which can damage the optic nerve and lead to vision loss.

The lens is responsible for focusing light onto the retina, enabling clear vision.

Cataracts are characterized by the clouding of the lens, leading to blurred vision.

Tissue engineering in regenerative medicine aims to create artificial corneas to replace damaged or diseased corneas.